Approximately one half of patients with metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer will develop brain metastases,1-8 a clinical situation for which treatments are limited; there are no US Food and Drug Administration–approved brain-metastasis–specific systemic treatments. Here, ERBB2 is linked to breast carcinoma.